A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)

drug protocol number

CRAD001A2433

drug sponsor

Novartis

drug study

Everolimus

drug trial site

Prince Sultan Military Medical City (Riyadh), King Fahad Specialist Hospital (Dammam)

drug status

Ongoing

drug phase